Rare disease patient finding technology | Volv

News:

1. We are deploying our state of the art methodology, inTrigue, in the UK with Sanofi to help clinicians recognise people living with Fabry and Pompe disease much earlier.

Fabry and Pompe disease in the UK

We are world-class leaders in applying AI to healthcare with a focus on rare or difficult-to-diagnose diseases.

Our mission is to speed science, reduce the cost of healthcare, close the diagnostic gap and improve outcomes for people living with disease.

Our leading AI methodology inTrigue uses machine learning to detect people with undiagnosed rare and orphan diseases in population-scale data such as electronic health and claims records. Our product inClude is designed to help rare disease innovators establish better clinical development strategies much earlier, by enriching disease understanding with new insights, thereby delivering increased value to healthcare providers, payers, and people living with disease alike.

Creativity + Expertise + AI = Healthcare Innovation

inTrigue

inTrigue: finding undiagnosed or misdiagnosed patients up to 8 years earlier

Find out more about inTrigue here:

Find out more ->

Automated disease learning is carried out from first principles, producing a mathematical representation of the disease as a starting point in the inTrigue process.

inTrigue is a standardised, repeatable methodology that produces robust models inspite of the obvious machine learning challenges presented by electronic health records (EHRs), which present with messy, gappy, sparse and unstructured data.

We deliver a 'human-interpretable" model that can be used by clinicians. It is developed in their language and using their terminology, and it has quantifiable predictive performance, derived from reverse engineering our complex models.

Healthcare systems vary country by country and in some cases region by region: clinician terms are different; coding is different; and often even the way disease is thought of and treated is different.

Volv creates impact across the healthcare spectrum

inTrigue creates novel predictors to help find patients much earlier in their journey from initial point of access to receiving care in the medical system. Deploying inTrigue algorithms intelligently into the healthcare system, helps to identify patients much earlier than before.

Click Here

inTrigue increases your understanding of the individual elements of the patient journey through ultimately to receiving care, providing valuable insights into the triggers for and incidences of misdiagnosis, so these can be addressed.

Click Here

inTrigue reshapes medical practice, helping specialists make better clinical diagnoses, allowing them to treat the precise cohorts of patients that will benefit most from your medicine.

Click Here

inTrigue finds patients you know exist but can’t find, and finds patients that you don’t know exist yet. It identifies patient cohorts, and enables precision case finding.

Click Here

Latest News Pages

Keep up to date and see what:

we are working on
events we are attending, and
white papers that have been published

Some of these events may result in a Volv presentation that you may wish to review for further inSight into what we do.

If you want to know what is coming up, remember to look at our News and Blog Section. Or you can contact us directly by emailing crudolf@volv.global

The Volv Team thanks you for reading this.

We are world-class leaders in applying AI to healthcare with a focus on rare or difficult-to-diagnose diseases. Our mission is to speed science, reduce the cost of healthcare, close the diagnostic gap and improve outcomes for people living with disease.

inTrigue

inTrigue: finding undiagnosed or misdiagnosed patients up to 8 years earlier

Find out more about inTrigue here:

We are world-class leaders in applying AI to healthcare with a focus on rare or difficult-to-diagnose diseases.

Our mission is to speed science, reduce the cost of healthcare, close the diagnostic gap and improve outcomes for people living with disease.